NCT05904886

IMbrave152: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab And Bevacizumab, With or without Tiragolumab, in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma ("SKYSCRAPER-14").

This is a Phase III research study called IMbrave152, also known as "SKYSCRAPER-14." It's a large-scale study designed to compare different treatment combinations for patients who have not received any prior treatment for their locally advanced or metastatic hepatocellular carcinoma (a type of liver cancer). Atezolizumab and Bevacizumab are two drugs that work in different ways to fight cancer. Atezolizumab boosts the immune system's ability to attack cancer cells, while bevacizumab targets the blood vessels that supply nutrients to tumors, which can help shrink them. Tiragolumab is another drug being tested in this trial. It's being evaluated to see if adding it to atezolizumab and bevacizumab improves treatment outcomes compared to using atezolizumab and bevacizumab alone. The study is "randomized," meaning patients are randomly assigned to one of the treatment groups. It's "double-blind," which means neither the patients nor the researchers know who is receiving which treatment (either the actual drugs or a placebo for comparison). This helps ensure unbiased results in evaluating how effective and safe each treatment combination is. The goal of IMbrave152 is to determine which combination of these drugs provides the best outcomes in terms of shrinking tumors, prolonging survival, and maintaining quality of life for patients with advanced liver cancer who have not yet been treated with any other therapies.

Phase III: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05904886

Clinical Trial Site: Sinai/Einstein

To see all available clinical trials click here.